LensGen® Closes $5.9 Million Financing

Irvine, Calif., March 2, 2023 – LensGen, Inc., a clinical stage ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the closing of a $5.9 million Bridge Financing. The financing was led by the corporate venture investment arm of HOYA Group.

Sumit Garg, M.D. Presented Thirty-Six Months Grail Study Visual Outcomes at the American Society of Cataract and Refractive Surgery Conference

San Diego, Calif., May 6, 2023 – Sumit Garg, M.D., Vice Chair of Clinical Ophthalmology & Medical Director at the Gavin Herbert Eye Institute, University

LensGen® Closes $5.9 Million Financing

Irvine, Calif., March 2, 2023 – LensGen, Inc., a clinical stage ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL)

Eric D. Donnenfeld, MD Presents 24 Months Grail Study Outcomes of the Juvene® IOL at the American Academy of Ophthalmology

AAO: October 1, 2022 A Look at a New Shape-Changing IOL Eric D. Donnenfeld, MD, shares the long-term refractive and contrast sensitivity outcomes of a